|
|
||||||||
From the Departments of Neurology (E.J.S., B.C., J.C.S.) and Biostatistics (J.M.), Mayo Clinic, Rochester, MN.
Address correspondence and reprint requests to Dr. Eric J. Sorenson, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; e-mail: sorenson.eric{at}mayo.edu
We assessed the effect of referral bias on patients with ALS treated at our medical center. A total of 132 subjects were treated by our center over the past 3 years. The referral population had a median survival of 29 months compared to 18 months for the local population (p = 0.007). Referral bias should be addressed when assessing the efficacy of self-selected therapies in the setting of a tertiary ALS clinic.
Disclosure: The authors report no conflicts of interest.
Received July 7, 2006. Accepted in final form October 23, 2006.
Related Article
Neurology 2007 68: 540-541.
This article has been cited by other articles:
![]() |
L. Pusztai, K. Broglio, F. Andre, W. F. Symmans, K. R. Hess, and G. N. Hortobagyi Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., October 1, 2008; 26(28): 4679 - 4683. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Logroscino, E. Beghi, O. Hardiman, A. Chio, J. D. Mitchell, R. J. Swingler, B. Traynor, for EURALS, E. J. Sorenson, J. Mandrekar, et al. EFFECT OF REFERRAL BIAS ON ASSESSING SURVIVAL IN ALS Neurology, August 28, 2007; 69(9): 939 - 940. [Full Text] [PDF] |
||||
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |